Tayla Stenta
Overview
Explore the profile of Tayla Stenta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore C, Williams E, Dyas R, Halman A, Stenta T, Khatri D, et al.
Clin Transl Sci
. 2025 Feb;
18(2):e70108.
PMID: 39899439
5-hydroxytryptamine-3 (5-HT) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially...
2.
Khatri D, Felmingham B, Moore C, Lazaraki S, Stenta T, Collier L, et al.
Br J Clin Pharmacol
. 2024 Aug;
90(11):2724-2741.
PMID: 39147586
Tacrolimus, a calcineurin inhibitor, is a highly effective immunosuppressant used in solid organ transplantation (SOT). However, it is characterized by a narrow therapeutic range and high inter-patient variability in pharmacokinetics....
3.
Stenta T, Assis M, Ayers K, Tucker E, Halman A, Gook D, et al.
Clin Transl Sci
. 2024 Jun;
17(6):e13827.
PMID: 38924306
For the same age, sex, and dosage, there can be significant variation in fertility outcomes in childhood cancer survivors. Genetics may explain this variation. This study aims to: (i) review...
4.
Conyers R, Halman A, Moore C, Stenta T, Felmingham B, Collier L, et al.
BMJ Open
. 2024 May;
14(5):e085115.
PMID: 38760050
Introduction: DNA-informed prescribing (termed pharmacogenomics, PGx) is the epitome of personalised medicine. Despite international guidelines existing, its implementation in paediatric oncology remains sparse. Methods And Analysis: Minimising Adverse Drug Reactions...
5.
Moore C, Lazarakis S, Stenta T, Alexander M, Nguyen R, Elliott D, et al.
Pharmacol Res Perspect
. 2023 Nov;
11(6):e01150.
PMID: 38013228
Pharmacogenomics remains underutilized in clinical practice, despite the existence of internationally recognized, evidence-based guidelines. This systematic review aims to understand enablers and barriers to pharmacogenomics implementation in pediatric oncology by...
6.
Lamande S, Ng E, Cameron T, Kung L, Sampurno L, Rowley L, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(19):e2211510120.
PMID: 37126720
Chondrocytes and osteoblasts differentiated from induced pluripotent stem cells (iPSCs) will provide insights into skeletal development and genetic skeletal disorders and will generate cells for regenerative medicine applications. Here, we...
7.
Patria Y, Stenta T, Lilianty J, Rowley L, Stanley E, Elefanty A, et al.
Stem Cell Res
. 2020 Aug;
48:101942.
PMID: 32771907
To produce in vitro models of human chondrodysplasias caused by dominant missense mutations in TRPV4, we used CRISPR/Cas9 gene editing to introduce two heterozygous patient mutations (p.F273L and p.P799L) into...